Relapsed or Refractory B Cell Non-Hodgkin Lymphoma research hub
3 indexed studies · 1 currently recruiting
- active not recruitingPHASE1
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
This study is looking into a new treatment called JNJ-90009530 for a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to find a safe dose and see how well it works.
United States · Australia · Israel - recruitingPHASE1
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This study looks at a new type of cell therapy called CAR T-cell therapy (AUTO1) for children and teenagers with types of blood cancer (leukaemia or lymphoma) that haven't responded to other treatments. It checks how safe and effective it is.
United States · Spain · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
This study is testing a new tablet medicine, Capivasertib (also called TRUQAP), for people in the UK with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to previous treatments. Researchers want to see if it shrinks the cancer and if it's safe to use.
Spain